[gnso-gac-closed-generics] Getting to a framework level

Alan Greenberg alan.greenberg at mcgill.ca
Fri Apr 21 20:37:42 UTC 2023


Sophie, without commenting on your document, I appreciate that we are not setting policy here, but it is critical that we provide sufficient guidance so that when the policy is written we won't be in  a position to react with "that was not what we intended".

Alan
________________________________
From: gnso-gac-closed-generics <gnso-gac-closed-generics-bounces at icann.org> on behalf of Sophie Hey <sophie.hey at comlaude.com>
Sent: Thursday, April 20, 2023 10:02 AM
To: gnso-gac-closed-generics at icann.org <gnso-gac-closed-generics at icann.org>
Subject: [gnso-gac-closed-generics] Getting to a framework level


Hi all,



Following our call the other day when we were very “in the weeds”, I have been trying to bring myself back to a framework level. I did so by challenging myself to try and summarise our work on one-page. The attached document is the outcome of my challenge to myself.



I do appreciate that what I have drafted is high-level. However, my sense after our call the other day is that we don’t want so much detail that we are attempting to write policy or even policy guidance. In any case, this group is not intended to create policy.



I am sharing this document because I hope it could be helpful as we try and draft our output.



Sophie



Sophie Hey
she/her
Policy Advisor

[cid:image001.png at 01D97399.1AFAB9D0]<https://comlaude.com/>

28-30 Little Russell Street,
London WC1A 2HN, UK
T +44 (0) 20 7421 8250
Ext 252

comlaude.com<http://comlaude.com>

[cid:image002.png at 01D97399.1AFAB9D0]<https://www.linkedin.com/company/com-laude> [cid:image003.png at 01D97399.1AFAB9D0] <https://twitter.com/comlaude?lang=en>  [cid:image004.png at 01D97399.1AFAB9D0] <https://www.facebook.com/ComLaude/>  [cid:image005.png at 01D97399.1AFAB9D0] <https://www.youtube.com/@comlaude>

[cid:image006.jpg at 01D97399.1AFAB9D0]

________________________________
The contents of this email and any attachments are confidential to the intended recipient. They may not be disclosed, used by or copied in any way by anyone other than the intended recipient. If you have received this message in error, please return it to the sender (deleting the body of the email and attachments in your reply) and immediately and permanently delete it. Please note that Com Laude Group Limited (the “Com Laude Group”) does not accept any responsibility for viruses and it is your responsibility to scan or otherwise check this email and any attachments. The Com Laude Group does not accept liability for statements which are clearly the sender's own and not made on behalf of the group or one of its member entities. The Com Laude Group is a limited company registered in England and Wales with company number 10689074 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England. The Com Laude Group includes Nom-IQ Limited t/a Com Laude, a company registered in England and Wales with company number 5047655 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Valideus Limited, a company registered in England and Wales with company number 6181291 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Demys Limited, a company registered in Scotland with company number SC197176 and registered office at 15 William Street, South West Lane, Edinburgh, EH3 7LL Scotland; Consonum, Inc. dba Com Laude USA and Valideus USA, a corporation incorporated in the State of Washington and principal office address at Suite 332, Securities Building, 1904 Third Ave, Seattle, WA 98101; Com Laude (Japan) Corporation, a company registered in Japan with company number 0100-01-190853 and registered office at 1-3-21 Shinkawa, Chuo-ku, Tokyo, 104-0033, Japan; Com Laude Domain ESP S.L.U., a company registered in Spain and registered office address at Calle Barcas 2, 2, Valencia, 46002, Spain. For further information see www.comlaude.com<https://comlaude.com>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://mm.icann.org/pipermail/gnso-gac-closed-generics/attachments/20230421/cb4e10ca/attachment-0001.html>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image001.png
Type: image/png
Size: 15281 bytes
Desc: image001.png
URL: <https://mm.icann.org/pipermail/gnso-gac-closed-generics/attachments/20230421/cb4e10ca/image001-0001.png>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image002.png
Type: image/png
Size: 2125 bytes
Desc: image002.png
URL: <https://mm.icann.org/pipermail/gnso-gac-closed-generics/attachments/20230421/cb4e10ca/image002-0001.png>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image003.png
Type: image/png
Size: 2949 bytes
Desc: image003.png
URL: <https://mm.icann.org/pipermail/gnso-gac-closed-generics/attachments/20230421/cb4e10ca/image003-0001.png>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image004.png
Type: image/png
Size: 2344 bytes
Desc: image004.png
URL: <https://mm.icann.org/pipermail/gnso-gac-closed-generics/attachments/20230421/cb4e10ca/image004-0001.png>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image005.png
Type: image/png
Size: 1972 bytes
Desc: image005.png
URL: <https://mm.icann.org/pipermail/gnso-gac-closed-generics/attachments/20230421/cb4e10ca/image005-0001.png>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image006.jpg
Type: image/jpeg
Size: 4660 bytes
Desc: image006.jpg
URL: <https://mm.icann.org/pipermail/gnso-gac-closed-generics/attachments/20230421/cb4e10ca/image006-0001.jpg>


More information about the gnso-gac-closed-generics mailing list